JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, leukemic mice bearing IM-resistant CML (T315I) have significantly prolonged their survival when treated with both JAK2 and HSP90 inhibitors (Ruxolitinib and AUY922).